COMP <GO>
CRSP vs UNH // ALTMAN Z-SCORE & DEBT/EQUITY
CRISPR Therapeutics AG (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: CRSP 2
— UNH 12
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: CRSP
LAST: $51.42 (-5.23%) • MKT CAP: $5.25B
balance-sheet
7.97
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
balance-sheet
3.12
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRSP VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRSP | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 88.57% | -47.57 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -30.60% | 11.47% | -42.07 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.59% | 6.48% | -13.07 | UNH | /fcf-yield <GO> |
| Operating Margin | -60.00% | 4.82% | -64.82 | UNH | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 3.14% | -63.14 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | 6.46% | -71.46 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 7.97 | 3.12 | +4.85 | CRSP | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.30% | 6.74% | +0.56 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.6 | 56.0 | -8.45 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.12 | 0.33 | +0.79 | CRSP | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.0x | 17.1x | +10.91 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.25B | $364.66B | -$359.41B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRSP REV | UNH REV | CRSP GROSS % | UNH GROSS % | CRSP FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.5M | $447.57B | 44.0% | 88.7% | -$345.9M | $16.07B |
| FY 2024 | $37.3M | $400.28B | 44.0% | 88.3% | -$144.7M | $20.70B |
| FY 2023 | $371.2M | $371.62B | 44.0% | 89.6% | -$277.1M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRSP // BETA 1.12
UNH // BETA 0.33